

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
0575/55424-A-PCT-USSerial No.
09/689,469

INFORMATION DISCLOSURE STATEMENT

(Include all sheets if necessary)

Applicant
Ann Marie Schmidt, et al.Filing Date
October 12, 2000Group
1646

RECEIVED

AUG 23 2001

TECH CENTER 1600/29

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
CY	5 8 6 4 0 1 8	4/16/96	Morser et al.			
CY	5 5 8 5 3 4 4		Vlassara et al.			

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
CY	WO 9 8 2 2 1 3 8	5/28/98	PCT				
CY	WO 9 7 3 9 1 2 1	10/23/97	PCT				
CY	WO 9 7 3 9 1 2 5	10/23/97	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Hori et al. 'The Receptor for Advanced Glycation Endproducts: Implications for the Development of Diabetic Vascular Disease. Fundam. Clin. Cardiol.' In: The Endothelium in Clinical Practice. January 1997, Chapter 11, pages 311-329;
	Chen et al. Amyloid-beta Peptide- Receptor for Advanced Glycation Endproduct Interaction Elicits Neuronal Expression of Macrophage-Colony Stimulating Factor: A Proinflammatory Pathway in Alzheimer Disease. Proc. Natl. Acad. Sci. 13 May 1997, Vol. 94, No. 10, pages 5296-5301;
	Schmidt et al. V-domain of Receptor for Advanced Glycation Endproducts (RAGE) Mediates Binding of AGEs: A Novel Target for Therapy of Diabetic Complications. Circulation. 21 October 1997, Vol. 96, No. 8 Suppl., page I37;
	Hori et al. The Receptor for Advanced Glycation Endproducts (RAGE) Is A Cell Surface Receptor for Amphotericin in the Developing Central Nervous System (CNS) to Promote Neurite Outgrowth. FASEB J. 1995, Vol. 9, No. 3, page A382; <i>not here</i>

EXAMINER

Christy HMX

DATE CONSIDERED

4/26/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this from with next communication to applicant.

Form PTO-1449

AUG 13 2001

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
0575/55424-A-PCT-USSerial No.
09689,469INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)Applicant
Ann Marie Schmidt, et al.Filing Date
October 12, 2000Group
1646

AUG 23 2001

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

International Search Report of International Application No. PCT/US99/08427, dated July 29, 1999;

cy Park, L., et al. (1998) "Suppression of accelerated diabetic atherosclerosis by soluble Receptor for AGE (sRAGE)" Nature Medicine, 4:1025-1031;

cy Vlassara, H., et al. (1995) "Identification of Galectin-2 as a high affinity binding protein for Advanced Glycation Endproducts (AGE): a new member of the AGE-Receptor complex" Molecular Medicine, 1:634-646;

cy Yan S-D, Chen X, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stern DM, Schmidt A-M: RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 1996;382:685-691.

EXAMINER

Christopher H. K.

DATE CONSIDERED

4/26/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this from with next communication to applicant.